ライフサイエンスコーパス: intravenous glucose tolerance

1 strema of rats fed a high-fat diet increased intravenous glucose tolerance and insulin sensitivity to

2 had normal levels of fasting blood glucose, intravenous glucose tolerance, and HbA1c, and 15 of 16 s

3 asurements of fasting plasma glucose, HbA1c, intravenous glucose tolerance, and insulin secretory res

4 Neither oral nor intravenous glucose tolerance changed significantly from

5 minimal model analyses of frequently sampled intravenous glucose tolerance (FSIGT) from the Insulin R

6 ous adipose biopsies, and frequently sampled intravenous glucose tolerance (FSIGT) testing were perfo

7 eloping T2D with annual measures of oral and intravenous glucose tolerance (IVGTT), body composition,

8 vity index (SI), disposition index (DI), and intravenous glucose tolerance (kg) were compared for eac

9 tion was assessed using a frequently sampled intravenous glucose tolerance test (first-phase insulin

10 aits were measured by the frequently sampled intravenous glucose tolerance test (four cohorts) or eug

11 ients were submitted to a frequently sampled intravenous glucose tolerance test (FSIGT) with the stim

12 rom the insulin-modified, frequently sampled intravenous glucose tolerance test (FSIGT), we estimated

13 The insulin-modified frequently sampled intravenous glucose tolerance test (FSIGTT) with minimal

14 ) was determined during a frequently sampled intravenous glucose tolerance test (FSIGTT).

15 ex (SI) calculated from a frequently sampled intravenous glucose tolerance test (FSIVGTT) after the m

16 lowing tests: 1) frequently sampled 0.3-g/kg intravenous glucose tolerance test (FSIVGTT) with MinMod

17 ated from the STM and by frequently sampling intravenous glucose tolerance test (FSIVGTT).

18 using an insulin-modified frequently sampled intravenous glucose tolerance test (FSIVGTT).

19 euglycemic hyperinsulinemic clamp (EHC), by intravenous glucose tolerance test (IVGTT) and by oral g

20 condition, we assessed glucose metabolism by intravenous glucose tolerance test (IVGTT) and euglycemi

21 The intravenous glucose tolerance test (IVGTT) and hyperglyc

22 exes with analogous indexes obtained from an intravenous glucose tolerance test (IVGTT) and hyperglyc

23 mpensation (AIR(G)) were assessed through an intravenous glucose tolerance test (IVGTT) and serum bio

24 For 100 years, the Intravenous glucose tolerance test (IVGTT) has been used

25 An intravenous glucose tolerance test (IVGTT) in the contro

26 sing clamp and minimal model analysis of the intravenous glucose tolerance test (IVGTT) to document p

27 e 2 diabetes and physiologic responses to an intravenous glucose tolerance test (IVGTT) to identify n

28 an oral glucose tolerance test (OGTT) and an intravenous glucose tolerance test (IVGTT) were performe

29 spike detection in humans during an in-vivo Intravenous Glucose Tolerance Test (IVGTT).

30 ted with insulin secretion as measured by an intravenous glucose tolerance test (r = 0.35).

31 dministration of exogenous insulin during an intravenous glucose tolerance test allows the use of the

32 ivity index (S(i)) from a frequently sampled intravenous glucose tolerance test among African-America

33 nsitivity (S(i)) from the frequently sampled intravenous glucose tolerance test among African-America

34 easured directly from the frequently sampled intravenous glucose tolerance test among black, Hispanic

35 s-sectional study in which we carried out an intravenous glucose tolerance test and an oral glucose t

36 an oral glucose tolerance test (OGTT) and an intravenous glucose tolerance test and by a dual-energy

37 sulin secretion using the frequently sampled intravenous glucose tolerance test and insulin sensitivi

38 ects were examined with a frequently sampled intravenous glucose tolerance test and meal tolerance te

39 ulin sensitivity (determined by the modified intravenous glucose tolerance test and minimal model ana

40 were determined by the tolbutamide-modified intravenous glucose tolerance test and minimal modeling,

41 veness (S(G)), which were determined from an intravenous glucose tolerance test and minimal modeling.

42 ody insulin sensitivity index (S(I)) with an intravenous glucose tolerance test and minimal modeling.

43 The intravenous glucose tolerance test and mixed meal tolera

44 second phase insulin release in response to intravenous glucose tolerance test and suppressed postpr

45 x ml(-1)), estimated by a frequently sampled intravenous glucose tolerance test and the minimal model

46 vity (SI), estimated by a frequently sampled intravenous glucose tolerance test and the minimal model

47 C-peptide increment to glucose during intravenous glucose tolerance test at days 90-120 after

48 ixed meal and underwent a frequently sampled intravenous glucose tolerance test before and after 2 ye

49 s undergoing SG or RYGB were studied with an intravenous glucose tolerance test before surgery and at

50 In contrast, postmeal and intravenous glucose tolerance test change over time in i

51 In vivo, the intravenous glucose tolerance test characterized oxyntom

52 CBV at rest and during an intravenous glucose tolerance test demonstrated a sustai

53 point was change in SI by frequently sampled intravenous glucose tolerance test from entry to week 12

54 mal model analysis of the frequently sampled intravenous glucose tolerance test in 1,625 men and wome

55 ulin sensitivity (S(I)) was measured with an intravenous glucose tolerance test in obese HIV+ women r

56 tance was measured with a frequently sampled intravenous glucose tolerance test in the Insulin Resist

57 The change over time in postmeal and intravenous glucose tolerance test insulin and C-peptide

58 Intravenous glucose tolerance test IVGTT and OGTT insuli

59 ulin action (Si), measured with the meal and intravenous glucose tolerance test models, was highly co

60 y and an insulin-modified frequently sampled intravenous glucose tolerance test on the second day.

61 K-values of an intravenous glucose tolerance test performed on day 14 w

62 Blood glucose profiles were normal, as were intravenous glucose tolerance test profiles.

63 l model analysis with the frequently sampled intravenous glucose tolerance test provides an effective

64 of EXN during mixed meal tolerance test and intravenous glucose tolerance test results in improved f

65 Finally, an intravenous glucose tolerance test revealed higher insul

66 Intravenous glucose tolerance test revealed that the rat

67 haracteristic loss of first-phase GSIS in an intravenous glucose tolerance test that is diagnostic of

68 = 389) had first-phase insulin release on an intravenous glucose tolerance test that was higher than

69 Intravenous glucose tolerance test was performed at base

70 An intravenous glucose tolerance test was performed during

71 A frequently sampled intravenous glucose tolerance test was used to obtain pr

72 , a hyperinsulinemic-euglycemic clamp and an intravenous glucose tolerance test were performed.

73 lucose levels, urine glucose levels, and the intravenous glucose tolerance test were used to monitor

74 n sensitivity (SI) by the frequently sampled intravenous glucose tolerance test with analysis by the

75 th a validated, 12-sample, insulin-enhanced, intravenous glucose tolerance test with minimal model an

76 the tolbutamide-modified, frequently sampled intravenous glucose tolerance test with minimal modeling

77 mes were changes in Si (measured by using an intravenous glucose tolerance test) and cardiovascular r

78 changes of portal insulin (as measured by an intravenous glucose tolerance test) versus slow changes

79 rinsulinemic clamp), insulin secretion (25-g intravenous glucose tolerance test), and endogenous gluc

80 ) in gSAT and aSAT, S(I) (frequently sampled intravenous glucose tolerance test), body composition (d

81 ntravenous test (e.g., a glucose clamp or an intravenous glucose tolerance test).

82 in secretory response (AIR; assessed by 25-g intravenous glucose tolerance test).

83 the curve and glucose disappearance rate on intravenous glucose tolerance test, all of which worsene

84 abolic testing by mixed meal tolerance test, intravenous glucose tolerance test, and arginine stimula

85 (S(I)) was measured by a frequently sampled intravenous glucose tolerance test, and CRP was measured

86 [AIR]), as derived from a frequently sampled intravenous glucose tolerance test, as well as common ca

87 The offspring had a baseline intravenous glucose tolerance test, at which time they w

88 Insulin sensitivity, measured by intravenous glucose tolerance test, decreased with age (

89 index (SI) assessed by a frequently sampled intravenous glucose tolerance test, insulin secretion ra

90 ic clamp), acute insulin response (AIR, 25-g intravenous glucose tolerance test, n = 118 normal gluco

91 ive insulin) had higher DRs than first-phase intravenous glucose tolerance test-derived incremental i

92 vely, as assessed using a frequently sampled intravenous glucose tolerance test.

93 x, both obtained from the frequently sampled intravenous glucose tolerance test.

94 (S(I)), as assessed by a frequently sampled intravenous glucose tolerance test.

95 sulin sensitivity (SI) was measured using an intravenous glucose tolerance test.

96 from the insulin-modified frequently sampled intravenous glucose tolerance test.

97 Insulin sensitivity as measured by an intravenous glucose tolerance test.

98 stimulation index of 4.02 in response to an intravenous glucose tolerance test.

99 sample, insulin-modified, frequently sampled intravenous glucose tolerance test.

100 the insulin curve in the first 10 min of the intravenous glucose tolerance test.

101 tation and animals were then subjected to an intravenous glucose tolerance test.

102 SI was determined by intravenous glucose tolerance test.

103 ponse and insulin sensitivity as measured by intravenous glucose tolerance test.

104 ady-state levels and continued through a 3-h intravenous glucose tolerance test.

105 vity was measured using the insulin-modified intravenous glucose tolerance test.

106 Insulin resistance was confirmed through an intravenous glucose tolerance test.

107 e (AIR) were derived from frequently sampled intravenous glucose tolerance test.

108 , acute insulin secretion was measured by an intravenous glucose tolerance test.

109 ) at 1 year after surgery, as assessed by an intravenous glucose tolerance test.

110 vity was assessed using a frequently sampled intravenous glucose tolerance test.

111 on (disposition index [DI]) were measured by intravenous glucose tolerance test.

112 was assessed by using the Frequently Sampled Intravenous Glucose Tolerance Test.

113 est followed by a skeletal muscle biopsy and intravenous glucose tolerance test.

114 sent and 41 underwent the frequently sampled intravenous glucose tolerance test.

115 directly measured using a frequently sampled intravenous glucose tolerance test.

116 d, and insulin sensitivity was determined by intravenous glucose tolerance test.

117 sample, insulin-enhanced, frequently sampled intravenous glucose tolerance test.

118 itivity was determined by frequently sampled intravenous glucose tolerance test.

119 tabolism as assessed by a frequently sampled intravenous glucose tolerance test.RESULTSChronic mirabe

120 phy, respectively; S(i) was assessed with an intravenous-glucose-tolerance test and minimal modeling.

121 were measured by using a frequently sampled intravenous-glucose-tolerance test and minimal modeling.

122 nemic-euglycemic glucose clamp technique and intravenous-glucose-tolerance test have indicated that i

123 tion were assessed with a frequently sampled intravenous-glucose-tolerance test, dual-energy X-ray ab

124 ty was estimated with the frequently sampled intravenous-glucose-tolerance test.

125 -sample, insulin-modified frequently sampled intravenous-glucose-tolerance test.

126 s measured by the disposition index after an intravenous-glucose-tolerance test.

127 were measured by using a frequently sampled intravenous-glucose-tolerance test.

128 e examined, and at 5-8 d postpartum (PP), an intravenous glucose-tolerance-test (GTT) and AT biopsies

129 asured insulin sensitivity index (S(I)) from intravenous glucose tolerance testing among African-Amer

130 Subjects underwent oral and intravenous glucose tolerance testing and arginine stimu

131 d first-phase insulin release in response to intravenous glucose tolerance testing, was observed afte

132 and disposition index (DI) were assessed by intravenous glucose tolerance testing.

133 virtually identical to that obtained during intravenous glucose tolerance tests (71.6+/-6.1% of tota

134 d 1 / fasting insulin (1/FI) from DPT-1 from intravenous glucose tolerance tests (DI).

135 lerance tests (OGTTs) and frequently sampled intravenous glucose tolerance tests (FSIGTs) were conduc

136 ch subject underwent four frequently sampled intravenous glucose tolerance tests (FSIGTT), one with t

137 such as glucose clamps or frequently sampled intravenous glucose tolerance tests (FSIGTTs).

138 and normalization of glucose disposal during intravenous glucose tolerance tests (IVGTT) remains crit

139 Intravenous glucose tolerance tests (IVGTTs) for assessm

140 dlimb lymph insulin profile during simulated intravenous glucose tolerance tests (IVGTTs) in anesthet

141 Intravenous glucose tolerance tests (IVGTTs) were perfor

142 Paired insulin-modified intravenous glucose tolerance tests (IVGTTs) were perfor

143 Oral glucose tolerance tests (OGTTs) and intravenous glucose tolerance tests (IVGTTs) were perfor

144 were infused into the third ventricle during intravenous glucose tolerance tests (IVGTTs).

145 l antibody-negative women underwent oral and intravenous glucose tolerance tests (OGTT; IVGTT), hyper

146 Oral and frequently sampled intravenous glucose tolerance tests (OGTTs and FSIGTs),

147 m a large sample of individuals studied with intravenous glucose tolerance tests demonstrated that in

148 administration protocols, we performed three intravenous glucose tolerance tests in each of seven obe

149 We performed hyperglycemic clamps and intravenous glucose tolerance tests in eight normal dogs

150 cutaneous and intraperitoneal sensors during intravenous glucose tolerance tests in eight swine.

151 Plasma samples from intravenous glucose tolerance tests of 2.5- and 5-month-

152 ed beta-cell function, we performed oral and intravenous glucose tolerance tests on mutation carriers

153 Intravenous glucose tolerance tests performed at 1, 2, a

154 Results of intravenous glucose tolerance tests performed on day 56

155 Intravenous glucose tolerance tests showed a rapid gluco

156 emic clamps in adults and frequently sampled intravenous glucose tolerance tests using Bergman minima

157 r sensor lag times (<4.2 min) in response to intravenous glucose tolerance tests versus burst NO-rele

158 ity (SI) as determined by frequently sampled intravenous glucose tolerance tests was measured over a

159 Oral and intravenous glucose tolerance tests were applied for est

160 Normal intravenous glucose tolerance tests were observed at day

161 Intravenous glucose tolerance tests were performed 2 wee

162 Frequently sampled intravenous glucose tolerance tests were performed befor

163 Intravenous glucose tolerance tests were performed befor

164 abetic, non-Amish subjects (n = 48), in whom intravenous glucose tolerance tests were performed, and

165 n levels returned to normal, and K values of intravenous glucose tolerance tests were significantly h

166 insulin secretion rates during both oral and intravenous glucose tolerance tests were used to generat

167 BCF) were determined from frequently sampled intravenous glucose tolerance tests, and total body fat

168 Based on intravenous glucose tolerance tests, dams consuming a WS

169 During intravenous glucose tolerance tests, tritiated glucose (

170 irst-phase insulin secretion, as measured by intravenous glucose tolerance tests, using up to 5,567 i

171 with normal glucose profiles in response to intravenous glucose tolerance tests.

172 f assigned treatment using both the oral and intravenous glucose tolerance tests.

173 xpansion, and 53 controls underwent oral and intravenous glucose tolerance tests.

174 e <126 mg/dl and were phenotyped by oral and intravenous glucose tolerance tests.

175 glycemic clamps), and insulin secretion [via intravenous-glucose-tolerance tests (IVGTTs)].Fifty-four

176 Intravenous-glucose-tolerance tests and oral-glucose-tol

177 Frequently sampled intravenous-glucose-tolerance tests measured insulin sen

178 Intravenous glucose tolerance was measured as the glucos

179 Intravenous glucose tolerance was reduced transiently fo